Lilly Reports Third-Quarter 2026 Results, Raises Full-Year Guidance
Eli Lilly reported third-quarter 2026 financial results and updated its full-year 2026 guidance.
Story updates
10:57:11 AM UTC
SquawkNews
Eli Lilly eleva beneficio neto un 16% a 6,45 mil millones de dólares en tercer trimestre de 2026
11:11:43 AM UTC
SquawkNews
By Kelly CloonanEli Lilly's quarterly revenue jumped on growing demand for its diabetes and obesity drugs Mounjaro and Zepbound.The results prompted the pharmaceutical company to raise its revenue guidance for the full year.Third-quarter profit came in at $6.45 billion, or $7.22 a share, compared w…
INDIANAPOLIS, Oct. 29, 2026 // -- Eli Lilly and Company (NYSE:LLY) today announced its financial results for the third quarter of 2026 and provided updated 2026 financial guidance."Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year ou…